-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Psychedelics R&D company Mindset Pharma (OTCQB:MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds.
The company recently announced the creation of three additional families (6, 7 and 8) of non-tryptamine psychedelic compounds. The new patent applications include drug candidates belonging to "Family 1," which is composed of second-generation psilocybin analogs.
According to Mindset, Family 1 compounds hold the potential of improving in size, safety and manufacturing when compared to psilocin and psilocybin. The group includes the first-elected clinical and most advanced drug candidate MSP-1014, a psilocybin-like entity that has demonstrated safety, improved efficacy and reduced potential side effects compared to first-generation psilocybin in preclinical studies and is set to be tested in clinical trials in 2023.
Furthermore, the company's IP portfolio strategy has made it recently file a provisional application with the US Patent and Trademark Office (USPTO) for the application of a novel chemical structural strategy to Family 1.
Mindset CEO James Lanthier explained: "Mindset is applying state of the art innovative medicinal chemistry to expand our rich pipeline of optimized psychedelic medications with improved overall efficacy and reduced toxicity profiles and we will continue to protect our compound pipeline and ensure that we provide the most effective options for patients with neurological and psychiatric disorders."
Mindset additionally announced grant options for up to 200,000 common shares at $0.55 each and expiring on September 6, 2023.
Photo courtesy of Pexels.
Psychedelics R&D company Mindset Pharma (OTCQB:MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of next-generation psychedelic compounds.
迷幻劑研發公司思維定勢製藥(OTCQB:MSSTF)已提交不少於16個國家的申請,包括東南亞主要市場,用於其關鍵的下一代迷幻化合物家族之一。
The company recently announced the creation of three additional families (6, 7 and 8) of non-tryptamine psychedelic compounds. The new patent applications include drug candidates belonging to "Family 1," which is composed of second-generation psilocybin analogs.
該公司最近宣佈再創建三個非色胺迷幻化合物家族(6、7和8)。新的專利申請包括毒品候選人屬於“家庭1”,它由第二代裸蓋菇素類似物組成。
According to Mindset, Family 1 compounds hold the potential of improving in size, safety and manufacturing when compared to psilocin and psilocybin. The group includes the first-elected clinical and most advanced drug candidate MSP-1014, a psilocybin-like entity that has demonstrated safety, improved efficacy and reduced potential side effects compared to first-generation psilocybin in preclinical studies and is set to be tested in clinical trials in 2023.
根據心態,家族1化合物具有潛在的在尺寸、安全性和製造方面的改進與裸蓋菇素和裸蓋菇素相比。該小組包括首次當選的臨牀和最先進的候選藥物MSP-1014,這是一種類似裸蓋菇素的實體,在臨牀前研究中已經證明瞭與第一代裸蓋菇素相比,它的安全性、有效性和減少了潛在的副作用,並將於2023年在臨牀試驗中進行測試。
Furthermore, the company's IP portfolio strategy has made it recently file a provisional application with the US Patent and Trademark Office (USPTO) for the application of a novel chemical structural strategy to Family 1.
此外,該公司的知識產權組合戰略最近向美國專利商標局(USPTO)提交了一份臨時申請,將一種新的化學結構策略應用於家族1。
Mindset CEO James Lanthier explained: "Mindset is applying state of the art innovative medicinal chemistry to expand our rich pipeline of optimized psychedelic medications with improved overall efficacy and reduced toxicity profiles and we will continue to protect our compound pipeline and ensure that we provide the most effective options for patients with neurological and psychiatric disorders."
思維定勢首席執行官詹姆斯·蘭蒂耶解釋説:“Mindset正在應用最先進的創新藥物化學來擴展我們豐富的優化迷幻藥物流水線,以提高整體療效和降低毒性。我們將繼續保護我們的複合體管道並確保我們為神經和精神障礙患者提供最有效的選擇。“
Mindset additionally announced grant options for up to 200,000 common shares at $0.55 each and expiring on September 6, 2023.
心態另行公佈授予選項最多20萬股普通股,每股0.55美元,2023年9月6日到期。
Photo courtesy of Pexels.
照片由Pexels提供。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧